- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06294678
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
February 28, 2024 updated by: Anhui Provincial Hospital
A Multicenter Randomized Controlled Study of the Effect of Stem Cell Infusion Time on the Development of aGVHD in Patients With Hematological Malignancies After Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation
To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Acute graft-versus-host disease (aGVHD) is a major complication and non-recurrent cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
The human biological clock uses recurring environmental cues such as light and food intake to establish 24-hour rhythmic changes in sleep, hormone secretion, metabolism, body temperature, and immune function.
Current clinical aGVHD prevention strategies focus on suppression of donor lymphocyte function by drugs or immunomodulatory cells, ignoring the impact of the recipient's own functional changes on the graft.
The applicant's previous retrospective cohort study found that the time of stem cell infusion severely affected the incidence of aGVHD and its severity after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT).
Due to the lack of prospective clinical trial results on the effect of stem cell infusion time on the occurrence of aGVHD after allo-HSCT in the international arena, as well as the possible influence of multiple confounding factors in the aforementioned single-center retrospective study, the present study intends to randomize patients according to the time of stem cell infusion, and to observe its effect on the incidence of aGVHD, other transplant-related complications, and long-term survival after allo-PBSCT of patients with hematological malignancies.
Study Type
Interventional
Enrollment (Estimated)
198
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiaoyu Zhu, ph.D
- Phone Number: 15255456091
- Email: xiaoyuz@ustc.edu.cn
Study Contact Backup
- Name: Yue Wu, M.D
- Phone Number: 13805601119
- Email: wuyue20160701@163.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230036
- The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Definite diagnosis of malignant hematologic disease before transplantation, age 12-60 years old, gender is not limited, race is not limited;
- Patients who are proposed to receive allo-PBSCT for the first time;
- Eastern Cooperative Oncology Group (ECOG) score 0-2;
- No serious organ failure and active infection;
- Voluntary open randomized controlled study to observe whether the time of stem cell infusion affects the occurrence of aGVHD after transplantation;
- Each subject must sign an informed consent form (ICF) indicating that he/she understands the purpose and procedures of the study and is willing to participate in the study; in view of the patient's condition, if the patient's own signature is not conducive to the treatment of his/her condition, the ICF will be signed by the legal representative.
Exclusion Criteria:
- Those with severe organ dysfunction or disease, such as severe disease and dysfunction of the heart, liver, kidneys and pancreas;
- Pregnant patients;
- Patients and/or authorized family members who refuse to undergo an open randomized controlled study to observe whether the time of stem cell infusion affects the occurrence of aGVHD after transplantation;
- Any life-threatening disease, physical condition, or organ system dysfunction that, in the opinion of the investigator, may compromise patient safety and put the results of the study at unnecessary risk; drug-dependent individuals; patients with uncontrolled psychiatric disorders; and individuals with cognitive dysfunction;
- Participants in other clinical studies that may affect aGVHD within 3 months;
- Those whom the investigator considers unsuitable for enrollment (e.g., those who anticipate that patients will not be able to adhere to the examination and treatment due to financial and other issues).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: the early infused group
infused stem cell within 11:30 am and 12:30 am
|
Randomization of patients according to the time of stem cell infusion
|
Sham Comparator: the late infused group
infused stem cell within 5:30 pm and 6:30 pm
|
Randomization of patients according to the time of stem cell infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of grade III to IV aGVHD
Time Frame: 100 days
|
The primary endpoint of the study will be the development of aGVHD in the first 100 days post-transplant.
Acute GVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria.
|
100 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The cumulative incidence of neutrophil engraftment at 28 days after transplantation
Time Frame: 28 days
|
neutrophil engraftment time was defined as the first of three consecutive days during which the neutrophil count was at least 0.5×10^9/L.
|
28 days
|
The cumulative incidence of platelet recovery at 100 days after transplantation
Time Frame: 100 days
|
Platelet recovery is defined as independence from platelet transfusion for at least 7 days with a platelet count of more than ≥ 100 × 10^9/L.
|
100 days
|
The cumulative incidence of chronic GVHD at 360 days after transplantation
Time Frame: 360 days
|
The severity of chronic GVHD was graded according to the 2014 NIH criteria.
|
360 days
|
The probability of GVHD-free, relapse-free survival(GRFS)
Time Frame: 360 days
|
The composite endpoint of GRFS was defined as the first events occurring after transplantation among Grade III to IV aGVHD, moderate to severe cGVHD, relapse, or death for any reason.
|
360 days
|
The probability of disease-free survival(DFS)
Time Frame: 360 days
|
The DFS was defined as the interval between transplantation and disease recurrence, death or the last follow-up date, whichever occurred first.
|
360 days
|
The probability of overall survival(OS)
Time Frame: 360 days
|
The OS was determined to be the time from the first day of transplantation until death from any cause or the last follow-up date.
|
360 days
|
The incidence of grade II to IV aGVHD
Time Frame: 100 days
|
The cumulative incidence of grade II to IV aGVHD in the first 100 days post-transplant.
aGVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria.
|
100 days
|
The cumulative incidence of transplant-related mortality at 180 days after transplantation
Time Frame: 180 days
|
The cumulative incidence of transplant-related mortality at 180 days after transplantation
|
180 days
|
The cumulative incidence of transplant-related mortality at 360 days after transplantation
Time Frame: 360 days
|
The cumulative incidence of transplant-related mortality at 360 days after transplantation
|
360 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Xiaoyu Zhu, ph.D, The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2024
Primary Completion (Estimated)
November 30, 2025
Study Completion (Estimated)
August 31, 2026
Study Registration Dates
First Submitted
February 28, 2024
First Submitted That Met QC Criteria
February 28, 2024
First Posted (Actual)
March 5, 2024
Study Record Updates
Last Update Posted (Actual)
March 5, 2024
Last Update Submitted That Met QC Criteria
February 28, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- infusion time & aGVHD-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Graft-versus-host Disease
-
Mesoblast, Inc.Quintiles, Inc.CompletedGrade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host DiseaseUnited States
-
University of LiegeTerminatedChronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host DiseaseBelgium
-
Jazz PharmaceuticalsCompletedAcute-graft-versus-host Disease | Graft-versus-host DiseaseUnited States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal
-
Jonsson Comprehensive Cancer CenterWithdrawnAcute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host DiseaseUnited States
-
AltruBio Inc.CompletedSteroid-refractory Acute Graft-versus-Host Disease | Treatment-refractory Acute Graft-versus-Host DiseaseUnited States
-
Shenzhen Xbiome Biotech Co., Ltd.Beijing Improve-Quality Tech.Co., Ltd.Recruiting
-
Cytopeutics Sdn. Bhd.Universiti Tunku Abdul RahmanActive, not recruitingAcute-graft-versus-host DiseaseMalaysia
-
Incyte CorporationTerminatedAcute Graft-versus-host DiseaseUnited States, Spain, France, Italy, United Kingdom, Germany
-
Incyte CorporationCompletedAcute Graft-versus-host DiseaseJapan
-
Central Hospital, Nancy, FranceUnknown
Clinical Trials on Time of stem cell infusion
-
Anhui Provincial HospitalNot yet recruitingAcute Graft-versus-host DiseaseChina
-
Children's Hospital of Chongqing Medical UniversityUnknown
-
Hospital Universitario Dr. Jose E. GonzalezSuspendedCardiomyopathy, DilatedMexico
-
Jianming TanUnknownOsteochondritis of the Femoral HeadChina
-
The University of Texas Health Science Center,...United States Department of Defense; U.S. Army Medical Research and Development...Active, not recruitingTBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Brain Injuries, AcuteUnited States
-
American CryoStem CorporationActive, not recruitingPost-Concussion SyndromeUnited States
-
Talaris Therapeutics Inc.Duke UniversityTerminatedNiemann-Pick Disease | Alpha-mannosidosis | Tay Sachs Disease | Sandhoff Disease | Metachromatic Leukodystrophy (MLD) | Hurler-Scheie Syndrome | Hurler Syndrome (MPS I) | Hunter Syndrome (MPS II) | Sanfilippo Syndrome (MPS III) | Krabbe Disease (Globoid Leukodystrophy) | Adrenoleukodystrophy (ALD and AMN) | Pelizaeus...United States
-
Cedars-Sinai Medical CenterJohns Hopkins University; National Heart, Lung, and Blood Institute (NHLBI); National... and other collaboratorsCompletedVentricular Dysfunction | Recent Myocardial InfarctionUnited States
-
Christian Medical College, Vellore, IndiaUnknownGraft vs Host DiseaseIndia
-
Talaris Therapeutics Inc.WithdrawnMultiple Sclerosis